Retatrutide vs Tirzepatide: Triple vs Dual Agonist
By DoseGauge Editorial · Updated 2026-06-12 · 5 min read
The two differences that matter are mechanism and status. Retatrutide is an investigational triple agonist that activates the GIP, GLP-1, and glucagon receptors. Tirzepatide is an FDA-approved dual agonist that activates the GIP and GLP-1 receptors, sold as Mounjaro and Zepbound. Retatrutide adds glucagon-receptor agonism to the two targets tirzepatide already hits. Both are once-weekly subcutaneous injections. There is no head-to-head trial between them, and this page does not say one is better. It reports mechanism, approval status, and why the trial numbers cannot be compared directly.
Mechanism
Tirzepatide activates two incretin pathways. It is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, which is how its FDA labels describe it. Those pathways increase glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite.
Retatrutide (Eli Lilly code LY3437943) adds a third target. It is a triple agonist of the GIP, GLP-1, and glucagon receptors. The added glucagon-receptor agonism is the structural difference from tirzepatide, and the Phase 2 literature frames it as a mechanism that may affect energy expenditure alongside the appetite and glycemic effects shared with the dual agonist. The clean factual line is the receptor count: three targets for retatrutide, two for tirzepatide.
Approval and evidence status
This is where the two diverge most sharply.
Tirzepatide is FDA-approved. It is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. It has finalized FDA labels, defined indications, and a completed Phase 3 programme behind those approvals.
Retatrutide is investigational and not FDA-approved for any indication as of June 2026. Its published efficacy evidence is the Phase 2 obesity trial (Jastreboff et al., NEJM 2023), and its Phase 3 programme (TRIUMPH) is ongoing, with some topline data beginning to read out. No FDA application or approval has been completed. So one drug is compared against an approved label and the other against trial data only, which is the core asymmetry of any retatrutide-versus-tirzepatide comparison.
Dosing at a glance
Both drugs are once-weekly subcutaneous injections that start low and step up. Tirzepatide follows its FDA label; retatrutide's figures come from the Phase 2 trial, not an approved schedule.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Mechanism | Triple GIP / GLP-1 / glucagon agonist | Dual GIP / GLP-1 agonist |
| Status | Investigational, not FDA-approved | FDA-approved (Mounjaro, Zepbound) |
| Route and frequency | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Dose source | Phase 2 trial escalation | FDA label titration |
| Escalation | 2 mg, then 4, 8, 12 mg (trial) | 2.5 mg start, 2.5 mg steps to 15 mg max (label) |
The tirzepatide column is the FDA titration: start at 2.5 mg weekly, increase in 2.5 mg steps no sooner than every 4 weeks, to a maximum of 15 mg weekly. The retatrutide column is the trial escalation, not a recommendation or an approved regimen. If you reconstitute either from a lyophilized vial, the dose-to-units arithmetic is the same, but the milligram scales differ, so do not reuse one drug's unit count for the other. Run each through its own calculator.
Why you cannot directly compare the trial numbers
It is tempting to line up a retatrutide weight-loss percentage next to a tirzepatide one and call it a ranking. That comparison is not valid. The figures come from different trials with different populations, durations, endpoints, and dose ranges, and no trial has randomized people to retatrutide versus tirzepatide head to head.
Cross-trial comparison ignores the things that move a result independent of the drug: baseline weight, enrollment criteria, trial length, placebo response, and statistical methods. The only way to know which produces a larger effect under matched conditions is a direct head-to-head trial, which does not exist for this pair. Until one does, the honest statement is that each drug has its own evidence, and the two sets of numbers are not interchangeable.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
There is no head-to-head trial, so there is no valid direct answer. Each drug's results come from separate trials with different designs and populations, which cannot be compared like for like. Retatrutide is also investigational, so its evidence is earlier-stage than tirzepatide's approved-label data.
What is the main difference between them?
Mechanism and status. Retatrutide is a triple GIP/GLP-1/glucagon agonist and is investigational. Tirzepatide is a dual GIP/GLP-1 agonist and is FDA-approved as Mounjaro and Zepbound. Both are once-weekly subcutaneous injections.
Are they dosed the same way?
Both are once weekly and both escalate from a low starting dose, but the schedules differ. Tirzepatide follows its FDA label (2.5 mg start, up to 15 mg). Retatrutide's escalation comes from the Phase 2 trial (2 mg up to 12 mg) and is not an approved regimen.
Can I compare their milligram doses directly?
No. The milligram scales differ and the schedules come from different sources (a trial for retatrutide, an FDA label for tirzepatide). A milligram of one is not equivalent to a milligram of the other. If you reconstitute either, run that drug's own dose through its own calculator.
Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.